Improved precision of Alzheimer’s disease fluid biomarkers when using Amyloid‐β<sub>40</sub> or non‐phosphorylated tau as a reference

Abstract Background Fluid biomarkers represent an informative and cost‐effective way to detect and monitor Alzheimer’s disease (AD). However, as we recently showed, the overall proteome average in CSF exhibits a non‐disease related average signal (inter‐individual variability), which can reduce the precision of concentration based CSF AD biomarkers. 1 Now, we therefore investigate if several already high performing CSF and plasma AD biomarkers can be improved by normalizing their concentration to a reference protein (e.g. Aβ40 and non‐phosphorylated mid‐region tau [nP‐tau]). Methods Using the BioFINDER‐2 (BF2) cohort (n=1908), we compared the associations between amyloid/tau‐PET load and CSF biomarkers (MTBR‐tau243, P‐tau217, P‐tau181, P‐tau205, Aβ42) alone versus in a ratio with a reference protein (e.g. CSF Aβ40 or nP‐tau) in linear regression models. We repeated this analysis for plasma biomarkers (P‐tau217, P‐tau181, P‐tau205, Aβ42) alone versus in a ratio with plasma Aβ40 or nP‐tau. Assays included mass spectrometry based (WashU) and immunoassays (Lilly and Elecsys). Results All concentration based CSF biomarkers, including MTBR‐tau243, showed significantly stronger association with tau‐PET load when applied in a ratio with CSF Aβ40 compared to alone (ΔR‐squared=0.0639‐0.213), Table 1 and Figure 1a‐1b. Similar results (but not all significant) were seen for associations with amyloid‐PET (ΔR‐squared=0.0161‐0.278), Figure 1c. A ratio with CSF nP‐tau significantly increased biomarker concordance with amyloid‐PET for all except MTBR‐tau243 (ΔR‐squared=‐0.0059‐0.188), but not tau‐PET (ΔR‐squared=‐0.044‐0.0626). For plasma biomarkers, ratios with both Aβ40 and nP‐tau led to stronger associations with tau‐PET (ΔR‐squared=0.0039‐0.120), while associations with amyloid‐PET mainly were improved in ratios with nP‐tau (ΔR‐squared=0.018‐0.123), Figure 1d‐1f. When comparing all biomarkers (Figure 2), highest correlation with tau PET was seen for MTBR‐tau243/Aβ40 in CSF (R‐squared=0.770) and P‐tau217/nP‐tau in plasma (R‐squared=0.666), and with amyloid‐PET for P‐tau217/nP‐tau in both CSF (R‐squared=0.689) and plasma (R‐squared=0.652). Conclusions CSF and plasma biomarkers show stronger association with tau‐PET and amyloid‐PET loads when applied in a ratio with a reference protein (e.g. Aβ40 or nP‐tau). Ongoing work involves validation in external cohorts, and longitudinal analyses to assess if a ratio approach also can reduce biomarker fluctuations within an individual. Karlsson, L. et al. Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases. BioRxiv (preprint) (2023) doi:10.1101/2023.06.08.544222.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2024-12-01
DOI
https://doi.org/10.1002/alz.085036
Primary Topic
Neurological Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Improved precision of Alzheimer’s disease fluid biomarkers when using Amyloid‐β40 or non‐phosphorylated tau as a reference

Alexa Pichet Binette, Randall John Bateman, Sebastian Palmqvist, Erik Stomrud et al.
Alzheimer s & Dementia
Neurological Disorders and Treatments
article

Improved precision of Alzheimer’s disease fluid biomarkers when using Amyloid‐β40 or non‐phosphorylated tau as a reference

Alexa Pichet Binette, Randall John Bateman, Sebastian Palmqvist, Erik Stomrud, Kaj Blennow, Yingxin He, Vitaliy Ovod, Niklas Mattsson, Oskar Hansson, Gemma Salvadó, Nicolas R. Barthélemy, Kalle Åström, Shorena Janelidze, Jacob W. Vogel, Kanta Horie, Linda Karlsson, Ida Arvidsson, James G. Bollinger
article en

Abstract

Abstract Background Fluid biomarkers represent an informative and cost‐effective way to detect and monitor Alzheimer’s disease (AD). However, as we recently showed, the overall proteome average in CSF exhibits a non‐disease related average signal (inter‐individual variability), which can reduce the precision of concentration based CSF AD biomarkers. 1 Now, we therefore investigate if several already high performing CSF and plasma AD biomarkers can be improved by normalizing their concentration to a reference protein (e.g. Aβ40 and non‐phosphorylated mid‐region tau [nP‐tau]). Methods Using the BioFINDER‐2 (BF2) cohort (n=1908), we compared the associations between amyloid/tau‐PET load and CSF biomarkers (MTBR‐tau243, P‐tau217, P‐tau181, P‐tau205, Aβ42) alone versus in a ratio with a reference protein (e.g. CSF Aβ40 or nP‐tau) in linear regression models. We repeated this analysis for plasma biomarkers (P‐tau217, P‐tau181, P‐tau205, Aβ42) alone versus in a ratio with plasma Aβ40 or nP‐tau. Assays included mass spectrometry based (WashU) and immunoassays (Lilly and Elecsys). Results All concentration based CSF biomarkers, including MTBR‐tau243, showed significantly stronger association with tau‐PET load when applied in a ratio with CSF Aβ40 compared to alone (ΔR‐squared=0.0639‐0.213), Table 1 and Figure 1a‐1b. Similar results (but not all significant) were seen for associations with amyloid‐PET (ΔR‐squared=0.0161‐0.278), Figure 1c. A ratio with CSF nP‐tau significantly increased biomarker concordance with amyloid‐PET for all except MTBR‐tau243 (ΔR‐squared=‐0.0059‐0.188), but not tau‐PET (ΔR‐squared=‐0.044‐0.0626). For plasma biomarkers, ratios with both Aβ40 and nP‐tau led to stronger associations with tau‐PET (ΔR‐squared=0.0039‐0.120), while associations with amyloid‐PET mainly were improved in ratios with nP‐tau (ΔR‐squared=0.018‐0.123), Figure 1d‐1f. When comparing all biomarkers (Figure 2), highest correlation with tau PET was seen for MTBR‐tau243/Aβ40 in CSF (R‐squared=0.770) and P‐tau217/nP‐tau in plasma (R‐squared=0.666), and with amyloid‐PET for P‐tau217/nP‐tau in both CSF (R‐squared=0.689) and plasma (R‐squared=0.652). Conclusions CSF and plasma biomarkers show stronger association with tau‐PET and amyloid‐PET loads when applied in a ratio with a reference protein (e.g. Aβ40 or nP‐tau). Ongoing work involves validation in external cohorts, and longitudinal analyses to assess if a ratio approach also can reduce biomarker fluctuations within an individual. Karlsson, L. et al. Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases. BioRxiv (preprint) (2023) doi:10.1101/2023.06.08.544222.

Alzheimer s & DementiaVol. 20(S2)
Statistics Sweden (SE), Lund University (SE), Science for Life Laboratory (SE), Sahlgrenska University Hospital (SE), Skåne University Hospital (SE), University of Gothenburg (SE)
Openalex Percentile: Top 71%
Neurological Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.